More Evidence Needed For Chiesi’s Ultra Orphan Lamzede, Says NICE
Executive Summary
Chiesi still has work to do to convince NICE that its ultra rare disease treatment Lamzede is a cost-effective treatment.
You may also be interested in...
Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018
New approvals in the EU were again dominated by oncology drugs in 2018, although medicines for infectious diseases were a close second. The number of orphan drugs more than doubled over the previous year, to 17. There were also some star arrivals in multiple sclerosis, genetic disorders, metabolism and migraine.
EU New Drug Approvals 2018: Anticancers, Orphans, The First CAR-Ts – And More
New drug approvals in the EU were again dominated by oncology in 2018, although medicines for infectious diseases came a close second. The number of orphan drugs more than doubled over the previous year, to 17. There were also some key new arrivals in the areas of multiple sclerosis, genetic disorders, metabolism and migraine.
UK: Commercial Framework Sheds Light On Working With NHS And NICE
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
Need a specific report? 1000+ reports available
Buy Reports